Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. FibroGen, Inc.
  6. News
  7. Summary
    FGEN   US31572Q8087

FIBROGEN, INC.

(FGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Plausibility And Undue Burden: A New Look Insufficiency After FibroGen v Akebia

11/12/2021 | 03:09am EST

FibroGen Inc. v Akebia Therapeutics Inc. and another company; Astellas Pharma Inc. v Akebia Therapeutics Inc. and other companies [2021] EWCA Civ 1279

What are the practical implications of this case?

If Arnold J's approach to insufficiency for want of plausibility had stood, it would have meant that pharmaceutical claims would have to enable substantially all of the compounds satisfying the structural definition as to the therapeutic efficacy. Equally, insufficiency for undue burden meant that the skilled team must be able to identify substantially all compounds covered by the claim without undue burden.

What the Birss LJ judgement does, is propose tests by which an invention, described using general terms, and which patent discloses a principle of general application, can reasonably be expected to work for anything falling within the scope of the claims. For plausibility (which the judge considers is best described as 'reasonable prediction') there is a three step test (although there is potentially a further, separate functional limitation in the first step namely, treatment of eg a disease). First, identify what falls within the scope of the claimed class; second, ask what is it intended to do; and third, whether it is possible to make a reasonable prediction the invention will work with substantially everything falling within the claimed scope. For undue burden, claims with a functional feature, or a mix of those and a structural feature, must make possible, without undue burden, the identification of compounds which satisfy the relevant test (eg treatment of a disease). It is not necessary to identify all or substantially all compounds that satisfy that test.

What was the background?

FibroGen owned two families of patents (A and B) relating to the treatment of anaemia associated with the kidney: Chronic Kidney Disease ('CKD' - family A) and Anaemia of Chronic Disease ('ACD' - family B). The A patents predated the B patents and constituted full prior art.

In family A the claims in issue comprised a heterocyclic carboxamide compound (selected from a named group), that inhibited hypoxia inducible factor (HIF) prolyl hydroxylase (PH) enzyme activity, in a medicament for increasing endogenous erythropoietin, in the prevention etc of anaemia associated with CKD. The family B patents had claims for the same compounds but were for treatment of ACD.

Akebia had a rival HIF-PH inhibitor (vadadustat), which was in clinical trials. They brought proceedings for revocation of the A and B patent families, met with a quia timet infringement action relating to the trials.

At trial, Arnold J concluded that the A patents were not obvious (over prior art called Epstein) but were invalid for insufficiency for lack of plausibility and undue burden. Akebia's vadadustat infringed on the basis of normal construction. The B patents were obvious in light of the A patent's original application and failed for insufficiency for the same reasons. Even if valid, there was no infringement (as the clinical trials were aimed at CKD).

FibroGen appealed the insufficiency findings for both families, and Akebia for the infringement finding.

What did the court decide?

On the two insufficiency bases, Birss LJ considered Arnold J's approaches were wrong, and overturned them. In order to do so, Birss LJ considered all of the law on insufficiency, both UK cases (including the Supreme Court decisions in Regeneron v Kymab and Warner Lambert v Generics), the EPO decisions, and (importantly) the decision of the Bundesgerichtshof ('BGH') in Dipeptidyl-Peptidase-Inhibitoren.

In agreeing with the BGH's reasoning that a claim to 'everything that works' without saying how to achieve that is unacceptable, Birss LJ also agreed with the BGH that a claim to the use of any compound with a functional feature (eg act as an inhibitor) for a therapeutic purpose (lower blood glucose), does not claim everything that works. Such language could also cover compounds not yet found, so for Arnold J to consider the skilled person must identify substantially all compounds covered by the claim meant he was wrong.

Birss LJ also clarified, based on EPO cases, that the second paragraph of 6.6.9 of the 9th Edition of EPO case law text book should be given a narrow reading. The term 'without undue burden' in that context refers to the ability of the skilled person to identify compounds within a structural class as having a functional feature ie with a functional feature, without undue burden, it must be possible to find compounds satisfying the test (eg acting as an inhibitor).

In deciding that the law of undue burden does not require the skilled person to identify substantially all compounds covered by the claims, this begged the question of how many compounds does the patentee need to disclose? The answer is some, but the key is that the skilled person, without undue burden, must be able to identify more beyond those stated in the patent. Moreover, the skilled person has to be able to work anywhere within the claim to apply the tests without undue burden, and identify if it is a claimed compound.

Birss LJ considered the A (and B) patents were not insufficient, and so were valid and infringed. He upheld Arnold J's conclusion that the B patents were obvious and so invalid.

This article was first published by Lexis®PSL on 27 August 2021

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mr Paul Harris
Dehns
St Bride's House
10 Salisbury Square
London
EC4Y 8JD
UK
Tel: 207632 7200
Fax: 207353 8895
E-mail: www.dehns.com
URL: www.dehns.com/

© Mondaq Ltd, 2021 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

Stocks mentioned in the article
ChangeLast1st jan.
AKEBIA THERAPEUTICS, INC. -7.11% 1.83 Delayed Quote.-19.03%
ASTELLAS PHARMA INC. 1.65% 1885 Delayed Quote.-0.88%
FIBROGEN, INC. -3.38% 14.01 Delayed Quote.-0.64%
All news about FIBROGEN, INC.
01/04FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference
AQ
2021FibroGen Exercises Exclusive License Option for Anti-CCR8 Monoclonal Antibody Program
MT
2021FibroGen Exercises Exclusive License Option for HiFiBiO's CCR8 Program
AQ
2021FibroGen, Inc. Exercises Exclusive License Option for HiFiBiO’s CCR8 Program
CI
2021FIBROGEN ALERT : Bragar Eagel & Squire, P.C. Is Investigating Fibrogen, Inc. on Behalf of ..
BU
2021PLAUSIBILITY AND UNDUE BURDEN : A New Look Insufficiency After FibroGen v Akebia
AQ
2021FibroGen Reports Net Income, Revenue Growth in Q3
MT
2021FIBROGEN INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS O..
AQ
2021FibroGen Reports Third Quarter 2021 Financial Results - Form 8-K
PU
2021FIBROGEN : Q3 Earnings Snapshot
AQ
More news
Analyst Recommendations on FIBROGEN, INC.
More recommendations
Financials (USD)
Sales 2021 266 M - -
Net income 2021 -219 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,85x
Yield 2021 -
Capitalization 1 299 M 1 299 M -
Capi. / Sales 2021 4,87x
Capi. / Sales 2022 6,61x
Nbr of Employees 599
Free-Float 92,0%
Chart FIBROGEN, INC.
Duration : Period :
FibroGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FIBROGEN, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 14,01 $
Average target price 16,00 $
Spread / Average Target 14,2%
EPS Revisions
Managers and Directors
Enrique A. Conterno Chief Executive Officer & Director
Juan Graham Chief Financial Officer
James A. Schoeneck Chairman
Michael Martinelli Senior Vice President-Technical Development
Elias Kouchakji Senior VP-Clinical Development & Drug Safety
Sector and Competitors
1st jan.Capi. (M$)
FIBROGEN, INC.-0.64%1 299
MODERNA, INC.-38.99%62 828
LONZA GROUP AG-20.54%48 784
IQVIA HOLDINGS INC.-17.54%44 443
SEAGEN INC.-20.08%22 592
ICON PUBLIC LIMITED COMPANY-18.28%20 601